search
Back to results

A Multicenter Trial of Radiofrequency Ablation vs. Surgery as Treatment of Papillary Thyroid Microcarcinoma.

Primary Purpose

Papillary Thyroid Microcarcinoma

Status
Recruiting
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Radiofrequency Ablation
Conventional Surgery
Sponsored by
Second Affiliated Hospital, School of Medicine, Zhejiang University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Papillary Thyroid Microcarcinoma focused on measuring Papillary Thyroid Microcarcinoma, Radiofrequency Ablation, Surgery

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Newly diagnosis of PTMC (largest dimension<10mm)
  • Age >=18 years old
  • Bethesda Category V or VI
  • Single nodule without thyroid capsule contact
  • Nodule has more than 3mm distance far from recurrent laryngeal nerve, carotid artery and trachea.
  • No clinical evidences show there is local or distant metastasis.
  • Without chemotherapy, radiotherapy and other related therapies.
  • Patients and their family member totally understand and sign the informed consent.

Exclusion Criteria:

  • Multifocal PTMC
  • Combined with other types of thyroid cancer or hyperthyroidism.
  • Contralateral vocal cord paralysis
  • With local or distant metastasis
  • Pregnant woman
  • With radiation exposure history

Sites / Locations

  • General Surgery Department, Tianjin Medical University General HospitalRecruiting
  • Department of Ultrasound, Second Affiliated Hospital, School of Medicine, Zhejiang UniversityRecruiting
  • Interventional Oncology Centre, State Institution "Grigoriev Intstitute for Medical Radiology NAMS of Ukraine"

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Radiofrequency Ablation

Conventional Surgery

Arm Description

Eligible participants with PTMC will be randomly assigned to this group and undergo radiofrequency ablation(RFA) procedure.

Eligible participants with PTMC will be randomly assigned to this group and undergo total/thyroid lobectomy procedure.

Outcomes

Primary Outcome Measures

Recurrent-free Survival Rate
record detecting recurrence of PTMC post-surgery or post-FRA

Secondary Outcome Measures

The Diameter of Lesion
record diameter reduce rate after RFA procedure
The Volume of Lesion
record volume reduce rate after RFA procedure
Postoperative Complications
record relevant complications after surgery or RFA
Serum Concentration of Serological Examination of Thyroid Function
record the serum concentration of TSH/T3/FT3/T4/FT4/TPOAb/TgAb/TRAb.
Medical Cost
record hospital expenditure
Hospital Duration
record hospital stay time
Patient Satisfaction: questionnaire
measured by satisfaction questionnaire designed by investigator group: items: 1.Are you satisfied with surgery? 2.Are you satisfied with the RFA procedure? scale range from 1 to 10; by the increasing of scale, the outcome is defined as good.
Anxiety index measured by psychological questionnaire
I feel more nervous and anxious than usual (anxiety) I feel scared for no reason (fear) I am easily upset or frightened (frightened) I think I might be going crazy (madness) There are 20 questions (No. 5-20 don't show because of the 999 words restriction). scale range from 1 to 4 For the question 5,9,13,17,18, the outcome is define as good by the increasing of scale. For the others, the outcome is defined as bad by the increasting of scale.(scale 1=No or very few, scale2=sometimes, scale3=often, scale4=always)
Overall Survival in Patients with PTMC
record 5 year overall survival

Full Information

First Posted
January 13, 2019
Last Updated
December 16, 2020
Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
search

1. Study Identification

Unique Protocol Identification Number
NCT03808779
Brief Title
A Multicenter Trial of Radiofrequency Ablation vs. Surgery as Treatment of Papillary Thyroid Microcarcinoma.
Official Title
A Multicenter, Randomized and Controlled Trial of Radiofrequency Ablation vs. Conventional Surgery as Treatment of Papillary Thyroid Microcarcinoma (PTMC)
Study Type
Interventional

2. Study Status

Record Verification Date
December 2020
Overall Recruitment Status
Recruiting
Study Start Date
June 1, 2019 (Actual)
Primary Completion Date
February 1, 2024 (Anticipated)
Study Completion Date
February 1, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The treatment of Papillary Thyroid Microcarcinoma (PTMC) nowadays varies among physicians, surgeons and radiologist. The recently published articles show that the prognosis of PTMC by different means of treatment strategies tends to be good. But multicentered, randomized, parallel and prospective study is rare. RFA is the abbreviation of "Radiofrequency Ablation", which tends to be an alternative strategy except conventional surgery. The investigator aims to confirm whether RFA for treating PTMC braces same effectiveness and prognosis comparing with conventional surgery. Besides, this trial also investigates the safety, economy and psychological quality under different treatments.
Detailed Description
The incidence of thyroid carcinoma, especially the papillary thyroid microcarcinoma (PTMC), has increasingly rapidly, due to the development of technologies of diagnosis, during the past 20 years. PTMC defined by the World Health Organization (WTO) as the largest dimension less than 1 cm. Previous autopsy study demonstrated that the lesions are normal in many people and accompany them latently until they die because of another reasons. The long-term outcome of PTMC is good and, as expected, more than 90% PTMC aren't progress for many years. Ultrasound-guided Radiofrequency Ablation (RFA) treatment was introduced to clinical practice few years ago. According to the 2015 American Thyroid Association (ATA) guideline, the treatment of radiofrequency and laser ablation are mentioned to be used in recurrent thyroid cancer. But clinical practice shows that the RFA treatment for low risk PTMC braces well effect,low financial budget,high safety and even rare postoperative complication. Although the cohort study was performed before, the real answer concerning about whether RFA is a rational choice for treating PTMC lacks more powerful evidences. The investigator considers to perform a randomized, controlled and multicenter study as a high-quality evidence and demonstrated the effect of PRF in low risk PTMC treatment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Papillary Thyroid Microcarcinoma
Keywords
Papillary Thyroid Microcarcinoma, Radiofrequency Ablation, Surgery

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
200 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Radiofrequency Ablation
Arm Type
Experimental
Arm Description
Eligible participants with PTMC will be randomly assigned to this group and undergo radiofrequency ablation(RFA) procedure.
Arm Title
Conventional Surgery
Arm Type
Active Comparator
Arm Description
Eligible participants with PTMC will be randomly assigned to this group and undergo total/thyroid lobectomy procedure.
Intervention Type
Procedure
Intervention Name(s)
Radiofrequency Ablation
Other Intervention Name(s)
RFA
Intervention Description
Patients were supine with the neck exposure completely during the procedure. Local anesthesia with 1% lidocaine was injected at the subcutaneous puncture site and the thyroid anterior capsule. If the distance between the tumor and critical cervical structures was less than 5 mm, normal saline was injected to form at least 1 cm distance between the tumor and the critical structure to prevent the unwilling thermal injury. RFA was performed using the moving-shot technique and RFA power was 5 W, if a transient hyperechoic zone did not form at the electrode tip within 5-10 seconds. The RFA extent exceeded the tumor edge to prevent marginal residue and recurrence. The ablation was terminated when all portions of the target ablation area had changed to hyperechoic zones.
Intervention Type
Procedure
Intervention Name(s)
Conventional Surgery
Other Intervention Name(s)
Total thyroidectomy/Thyroid lobectomy
Intervention Description
Patient is performed total thyroidectomy or thyroid lobectomy depending on the intraoperative situation, disease condition and comprehensive judge by surgeon. Patients are routinely disinfected and spread the drapes after general anesthesia. Neck skin, fat and placenta muscle are incised and separated successively. The flap is separated to the upper edge of thyroid cartilage, neck white line is incised and anterior muscle group is separated. Then both sides thyroid lobes are exposed. Cut off the isthmus, ligature the thyroid artery, cut off the upper pole. Ligature and cut off the ipsilateral thyroid vein. Reveal and protect the ipsilateral recurrent laryngeal nerve and the parathyroid gland during the entire process.
Primary Outcome Measure Information:
Title
Recurrent-free Survival Rate
Description
record detecting recurrence of PTMC post-surgery or post-FRA
Time Frame
5 years
Secondary Outcome Measure Information:
Title
The Diameter of Lesion
Description
record diameter reduce rate after RFA procedure
Time Frame
5 years
Title
The Volume of Lesion
Description
record volume reduce rate after RFA procedure
Time Frame
5 years
Title
Postoperative Complications
Description
record relevant complications after surgery or RFA
Time Frame
up to 12 months
Title
Serum Concentration of Serological Examination of Thyroid Function
Description
record the serum concentration of TSH/T3/FT3/T4/FT4/TPOAb/TgAb/TRAb.
Time Frame
up to 12 months
Title
Medical Cost
Description
record hospital expenditure
Time Frame
up to 12 months
Title
Hospital Duration
Description
record hospital stay time
Time Frame
through study completion, an average of 7 days
Title
Patient Satisfaction: questionnaire
Description
measured by satisfaction questionnaire designed by investigator group: items: 1.Are you satisfied with surgery? 2.Are you satisfied with the RFA procedure? scale range from 1 to 10; by the increasing of scale, the outcome is defined as good.
Time Frame
5 years
Title
Anxiety index measured by psychological questionnaire
Description
I feel more nervous and anxious than usual (anxiety) I feel scared for no reason (fear) I am easily upset or frightened (frightened) I think I might be going crazy (madness) There are 20 questions (No. 5-20 don't show because of the 999 words restriction). scale range from 1 to 4 For the question 5,9,13,17,18, the outcome is define as good by the increasing of scale. For the others, the outcome is defined as bad by the increasting of scale.(scale 1=No or very few, scale2=sometimes, scale3=often, scale4=always)
Time Frame
up to 5 years
Title
Overall Survival in Patients with PTMC
Description
record 5 year overall survival
Time Frame
5 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Newly diagnosis of PTMC (largest dimension<10mm) Age >=18 years old Bethesda Category V or VI Single nodule without thyroid capsule contact Nodule has more than 3mm distance far from recurrent laryngeal nerve, carotid artery and trachea. No clinical evidences show there is local or distant metastasis. Without chemotherapy, radiotherapy and other related therapies. Patients and their family member totally understand and sign the informed consent. Exclusion Criteria: Multifocal PTMC Combined with other types of thyroid cancer or hyperthyroidism. Contralateral vocal cord paralysis With local or distant metastasis Pregnant woman With radiation exposure history
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Pintong Huang, director
Phone
+8618857168333
Email
huangpintong@126.com
First Name & Middle Initial & Last Name or Official Title & Degree
jifan Chen, collegue
Phone
+8613605771565
Email
chenjifan0619@163.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Pintong Huang, director
Organizational Affiliation
Department of Ultrasound, Second Affiliated Hospital, School of Medicine, Zhejiang University
Official's Role
Principal Investigator
Facility Information:
Facility Name
General Surgery Department, Tianjin Medical University General Hospital
City
Tianjin
State/Province
Tianjin
ZIP/Postal Code
022
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jie Zhang, director
Phone
+8615822798742
Email
wzq_bf@163.com
First Name & Middle Initial & Last Name & Degree
Ruoyu Jiang, collegue
Phone
+8618622632394
Email
jiangruoyu000@aliyun.com
Facility Name
Department of Ultrasound, Second Affiliated Hospital, School of Medicine, Zhejiang University
City
Hangzhou
State/Province
Zhejiang
ZIP/Postal Code
0571
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pintong Huang, director
Phone
+8618857168333
Email
huangpintong@126.com
First Name & Middle Initial & Last Name & Degree
Jifan Chen, collegue
Phone
+8613605771565
Email
chenjifan0619@163.com
Facility Name
Interventional Oncology Centre, State Institution "Grigoriev Intstitute for Medical Radiology NAMS of Ukraine"
City
Kharkiv
ZIP/Postal Code
61024
Country
Ukraine
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sviatoslav Balaka
Phone
+380509356958
Email
balaka.svjat@gmail.com
First Name & Middle Initial & Last Name & Degree
Hennadii Hrechikhin
Phone
+380509188586
Email
interv.oncology@gmail.com

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

A Multicenter Trial of Radiofrequency Ablation vs. Surgery as Treatment of Papillary Thyroid Microcarcinoma.

We'll reach out to this number within 24 hrs